Large analyses presented at major nephrology meetings and published in JAMA reinforce that SGLT2 inhibitors provide kidney protection across a wide spectrum of patients, including people with and without diabetes and across varying levels of albuminuria and glomerular filtration rate. Meta‑analyses and pooled clinical data show reductions in renal outcomes and hospitalizations for heart failure. A detailed JAMA report highlighted heterogeneity in absolute benefit by diabetes status and albuminuria level, offering clinicians more granular guidance on which patient subgroups are likeliest to derive the largest risk reductions. Presenters emphasized that baseline kidney function and albuminuria modify effect size but do not eliminate benefit for many groups. The body of evidence supports broader routine use of SGLT2 inhibitors in nephrology practice while underscoring the need for individualized risk assessment and monitoring, particularly for patients with advanced CKD or low albuminuria.